Program
Cross-over to JYP0322
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Guangzhou JOYO Pharma.
Furthest: phase 3, since Aug 19, 20251 company-led study, 1 open or runningNext primary completion: Oct 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou JOYO Pharma | 11 open or running | phase 3since Aug 19, 2025 | Aug 19, 2025 | Oct 31, 2027phase 3 · NCT07154368 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2025First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07154368 · 207 planned
Ahead
- Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154368
TargetBeta
ROS1 →read by rule
“JYP0322 is an orally available inhibitor of ROS1 (coded by the gene ROS1).”study text, by rule · the study
Other programs on ROS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| taletrectinibrule | Nuvation Bio | phase 3 | 11 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| Fudotinibrule | Guangzhou JOYO Pharma | phase 3 | 3 |
| Radiosensitizer VS-101rule | vspharmtech-co-ltd | phase 2 | 2 |
| ROS1/NTRK Inhibitor ANS03rule | avistone-biotechnology-co-ltd | phase 1 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07154368Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Oct 31, 2027 | 207 |
How it is read
Names in the registry
- “Cross-over to JYP0322”, 1 entry
Codes read as this program: JYP0322.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.